TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ASTRAZENECA TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ASTRAZENECA Stock
Certificat
DE000SH5HBK1
| Delayed Deutsche Boerse AG 02:14:03 2024-05-21 EDT | ||
| 3.07 EUR | -2.23% |
|
| Current month | -0.95% | ||
| 1 month | +70.65% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-05-21 | 3.07 | -2.23% |
| 24-05-20 | 3.14 | +0.32% |
| 24-05-17 | 3.13 | -1.88% |
| 24-05-16 | 3.19 | -5.90% |
| 24-05-15 | 3.39 | +1.80% |
Delayed Quote Deutsche Boerse AG
Last update May 21, 2024 at 02:14 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SH5HBK |
| ISIN | DE000SH5HBK1 |
| Date issued | 2022-02-16 |
| Strike | 9,454 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.59 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.01 € |
|---|---|
| Lowest since issue | 0.19 € |
| Spread | 0.01 € |
| Spread % | 0.31% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
168.1
USD
Spread / Average Target
+9.41%
- Stock Market
- Certificates
- Certificat